Intra-Cellular Therapies
在场
高管
查看带有其 16 名主要高管的组织结构图
Intra-Cellular Therapies 搜索最多的简介
- Sharon Mates, President, Chairman and Chief Executive Officer
- Rene Salas, Director
- Rory Riggs, Director
高管在Intra-Cellular Therapies变化
- Sanjeev NarulaSanjeev Narula 将于20248月12作为 Chief Financial Officer 加入公司 (新闻发布的2024八月7号).
- Michael Halstead 曾任 Executive Vice President and General Counsel, 现升职为 President (新闻发布的2024三月20号).
创建提醒
跟踪 Intra-Cellular Therapies 的高管变动
生物技术
Intra-Cellular Therapies 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Intra-Cellular Therapies 的最新新闻稿
- Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences | Intra-Cellular Therapies Inc.
- Press Releases | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast | Intra-Cellular Therapies Inc.
- Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder | Intra-Cellular Therapies Inc.
- View more press releases Close
通过电子邮件
